Generic Substitution and Prescription Drug Prices PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Generic Substitution and Prescription Drug Prices PDF full book. Access full book title Generic Substitution and Prescription Drug Prices by Alison Masson. Download full books in PDF and EPUB format.
Author: Alison Masson
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 366
Get Book Here
Book Description
Author: Alison Masson
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 366
Get Book Here
Book Description
Author: Alison Masson
Publisher:
ISBN:
Category :
Languages : en
Pages : 580
Get Book Here
Book Description
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book Here
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Alison Masson
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 0
Get Book Here
Book Description
Author: Theodore Goldberg
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 584
Get Book Here
Book Description
Author:
Publisher: U.S. Government Printing Office
ISBN:
Category : Business & Economics
Languages : en
Pages : 94
Get Book Here
Book Description
Author: Khandaker Nayeemul Islam
Publisher:
ISBN:
Category :
Languages : en
Pages : 184
Get Book Here
Book Description
Increasing health care costs have made management of Medicaid services to provide low income families through Medicaid programs critical in the recent times. The number of Medicaid beneficiaries in Michigan has increased over the years mainly due to the downsizing of auto sectors. Currently, states spend almost 16 percent of their budget for Medicaid, making it the second largest item in the budget for most. Prescription drugs are a significant part of Michigan's Medicaid costs. Higher costs caused a tremendous fiscal burden on Michigan in administering the program and providing prescription drugs for its patients. Michigan has implemented several strategies for Medicaid since 2001, which have brought modest results in terms of Medicaid cost containment. An AARP report found that 80 percent of drugs have therapeutic equivalents or generics available in the market while 20 percent of drugs have no generic substitutions. But depending on the nature of diseases generic substitutions for Medicaid prescription drugs could be much higher than 80 percent. Previous research suggests that Michigan has the potential to increase generic substitutions at least 10 percent to 15 percent. This study examined whether a generic substitution policy would be an efficient and effective cost containment strategy for Michigan Medicaid prescription drug programs. This research emphasized three questions: First, would a generic substitution policy be an efficient strategy in containing Medicaid prescription drug program costs for Michigan? Second, did any heavily used brand drugs exist which had generic equivalents allowing Michigan to safely reduce Medicaid prescription drug costs by implementing a generic substitution policy? Third, if the answer was yes to both questions, then approximately what amount could Michigan save per year by implementing the generic substitution policy? This research found that Michigan could save 170 million dollars by implementing a generic substitution policy in the prescription drugs program within the selected six year period between 1999 to 2010 . In 2010, Michigan could save more than 16 million dollars by only prescribing generics, instead of ten brand drugs. A total savings from generics could be approximately 40 million dollars if only generics were prescribed instead of brand drugs. The total amount could be much higher if the multi-vitamin category was included.
Author: Julie Ann Somers
Publisher: DIANE Publishing
ISBN: 1437940390
Category : Health & Fitness
Languages : en
Pages : 36
Get Book Here
Book Description
This is a print on demand edition of a hard to find publication. Contents:(1) Overview of the Medicare Prescription Drug Benefit Program: Design of the Medicare Prescription Drug Benefit; Distribution of Spending in Medicare Part D; The Role of Private Plans in Medicare Part D; (2) Generic Drugs in Medicare Part D: Generic Substitution; Therapeutic Substitution; Comparing Potential Savings from Generic and Therapeutic Substitution; (3) Implications of Future Developments: First-Time Generic Entry; New Brand-Name Drugs; Biologics. (4) Appendix: Description of Data Used in This Analysis. Charts and tables.
Author: Robin A. Cohen
Publisher:
ISBN:
Category : Drug utilization
Languages : en
Pages : 12
Get Book Here
Book Description
Author: Elias B. Toft
Publisher: Nova Snova
ISBN: 9781536176681
Category :
Languages : en
Pages : 248
Get Book Here
Book Description
Chapter 1 examines the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on the Federal and state budgets, and on American families. Chapter 2 addresses frequently asked questions about government and private-sector policies that affect drug prices and availability. Among the prescription drug topics covered are federally funded research and development, regulation of direct-to-consumer advertising, legal restrictions on reimportation, and federal price negotiation. The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at discounted prices to covered entitiesâeligible clinics, hospitals, and othersâin order to have their drugs covered by Medicaid. Covered entities are only allowed to provide 340B drugs to certain eligible patients. Chapter 3 reviews the Health Resources and Services Administration's (HRSA) oversight of the 340B Program to ensure compliance with program rules. In 2017, nearly 60% of U.S. adults aged 18â64 reported being prescribed medication in the past 12 months. Approximately 70% of prescription medications carry out-of-pocket costs. Strategies to reduce prescription drug costs at the individual level are discussed in chapters 4 and 5. Each year, Americans pay more for prescription drugs, and rising drug prices have a disproportionate impact on older Americans. Chapter 6 examines the history of rising drug prices for the brand-name drugs most commonly prescribed for seniors. Generic drugsâcopies of brand-name drugsâlead to significant cost savings. Before a generic drug can be marketed, FDA must approve the generic drug application. According to FDA, applications go through an average of three cycles of review before being approved, which may take years. Chapter 7 examines 1) the first review cycle approval rate of generic drug applications in recent years and factors that may have contributed to whether applications were approved; and 2) changes FDA has made to increase the first review cycle approval rate.
